Morgan Stanley Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $226.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Laaman is a 5-star analyst with an average return of 11.7% and a 64.17% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Disc Medicine, Exelixis, and BridgeBio Pharma.

In addition to Morgan Stanley, Jazz Pharmaceuticals also received a Buy from Needham’s Ami Fadia in a report issued today. However, on the same day, TipRanks – xAI reiterated a Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ).

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.13 billion and a net profit of $251.41 million. In comparison, last year the company earned a revenue of $1.05 billion and had a net profit of $215.06 million

Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Most recently, in December 2025, Mary Elizabeth Henderson, the SVP Tech. Op of JAZZ sold 2,238.00 shares for a total of $379,363.38.